Keros Therapeutics, Inc. KROS
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Kelly Shi | Jefferies | 62.02 $ | 107 $ | 44.98 % | 05/11/2024 |
| Srikripa Devarakonda | Truist Financial | 62.02 $ | 100 $ | 37.98 % | 05/11/2024 |
| Vamil Divan | Guggenheim | 55.8 $ | 96 $ | 40.20 % | 23/09/2024 |
| Joseph Catanzaro | Piper Sandler | 44.65 $ | 105 $ | 60.35 % | 18/06/2024 |
| Julian Harrison | BTIG | 31.79 $ | 80 $ | 48.21 % | 27/07/2022 |
| Joseph Catanzaro | Piper Sandler | 39.92 $ | 120 $ | 80.08 % | 18/05/2022 |